A perspective on viral load testing.

J. Levin
1995-12-01
Abstract: Roche Molecular Systems and Chiron Inc. are filing for approval of their viral load tests. Viral load assays, used in all protease inhibitor trials, will eventually be used to screen blood products and plasma. The tests, which measure HIV RNA, can identify individuals at high risk of disease progression. However, the tests are still considered investigational by the FDA. While increases or decreases in viral load relative to disease progression have not been firmly established, most data so far supports a correlation. A clearly defined understanding of HIV RNA tests would refine the structure of AIDS clinical trials, allowing drugs to be studied in fewer people for a shorter time. The FDA needs to evaluate the equivalency between different viral load tests and establish procedural standards for laboratories using them.
What problem does this paper attempt to address?